MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies target structures within the neuromuscular junction, affecting neuromuscular transmission. Muscle-specific tyrosine kinase receptor-associated MG (MuSK-MG) is a rare, often more severe, subtype of the disease with different path...
Main Authors: | Edyta Dziadkowiak, Dagmara Baczyńska, Marta Waliszewska-Prosół |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/13/6/556 |
Similar Items
-
Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
by: Dipesh Chhetri, et al.
Published: (2025-02-01) -
Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis
by: Siripong Chayanopparat, et al.
Published: (2025-02-01) -
Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
by: Yung-Chuan Huang, et al.
Published: (2008-07-01) -
Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
by: Amber Eker, et al.
Published: (2020-08-01) -
Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
by: Fangyi Shi, et al.
Published: (2024-11-01)